Trials / Unknown
UnknownNCT05512559
Body Composition Analysis and Time to Emergence From Remimazolam
Value of Body Composition Analysis in Predicting Delayed Emergence From Remimazolam-based General Anesthesia: A Prospective Observational Study.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 90 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Remimazolam is a novel general anesthetic drug. The time to emergence from remimazolam-based general anesthesia is variable among patients, but little is known about the risk factors for delayed emergence. We believe that information from body composition analysis may be helpful in understanding which patients are more likely to show delayed emergence from remimazolam.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | body composition analysis | Body composition analysis by bioelectrical impedance measurement, just before induction of anesthesia. |
Timeline
- Start date
- 2022-09-05
- Primary completion
- 2022-12-30
- Completion
- 2023-03-01
- First posted
- 2022-08-23
- Last updated
- 2023-01-04
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05512559. Inclusion in this directory is not an endorsement.